Cravath, Faegre Steer Novartis' $2.1B Deal For Endocyte
Novartis AG said Thursday it will take over cancer therapy firm Endocyte Inc. in a $2.1 billion deal, with Cravath Swaine & Moore LLP guiding the Swiss pharmaceutical giant and Faegre...To view the full article, register now.
Already a subscriber? Click here to view full article